Management of Ureteral Obstruction Due to Advanced Malignancy: Optimizing Therapeutic and Palliative Outcomes

Journal of Urology

Volumn 180, Issue 2, 2008, Pages 444-450

  Kouba, Erik ^a   Wallen, Eric M ^a   Pruthi, Raj S ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

neoplasms; quality of life; stents; ureter; ureteral obstruction

Indexed keywords

AMILORIDE; AMITRIPTYLINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ELECTROLYTE; KETAMINE; LOSARTAN; MEMANTINE; METHADONE; MORPHINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAPAVERINE; PARECOXIB; PRAZOSIN; PREDNISONE; PROSTAGLANDIN; SPASMOLYTIC AGENT; STEROID; TAMSULOSIN; VERAPAMIL;

ABDOMINAL CRAMP; ADVANCED CANCER; ANOREXIA; BLADDER CANCER; BREAST CANCER; COLORECTAL CANCER; FLANK PAIN; HUMAN; KIDNEY COLIC; NAUSEA; NEPHROSTOMY; NONHUMAN; OBSTRUCTIVE UROPATHY; PAIN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PELVIS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL; UREMIA; URETER OBSTRUCTION; URETER STENT; URETER SURGERY; URETERAL DECOMPRESSION; URINARY TRACT INFECTION; UTERINE CERVIX CANCER; VOMITING;

BALLOON DILATATION; DECOMPRESSION, SURGICAL; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; STENTS; TREATMENT OUTCOME; URETERAL NEOPLASMS; URETERAL OBSTRUCTION; UROGENITAL NEOPLASMS;

EID: 46449116984     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.04.008     Document Type: Review

References (45)

1. Russo P. Ureteral obstruction and stents: still a difficult problem for patients and urologists alike. J Urol 174 (2005) 2088
2. Shekarriz B., Shekarriz H., Upadhyay J., Banerjee M., Becker H., Pontes J.E., et al. Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer 85 (1999) 998
3. Romero F.R., Broglio M., Pires S.R., Roca R.F., Guibu I.A., and Perez M.D. Indications for percutaneous nephrostomy in patients with obstructive uropathy due to malignant urogenital neoplasias. Int Braz J Urol 31 (2005) 117
4. Ganatra A.M., and Loughlin K.R. The management of malignant ureteral obstruction treated with ureteral stents. J Urol 174 (2005) 2125
5. Desgrandchamps F., Leroux S., Ravery V., Bochereau G., Menut P., Meria P., et al. Subcutaneous pyelovesical bypass as replacement for standard percutaneous nephrostomy for palliative urinary diversion: prospective evaluation of patient's quality of life. J Endourol 21 (2007) 173
6. Roza C., and Laird J.M. Pressor responses to distension of the ureter in anaesthetised rats: characterisation of a model of acute visceral pain. Neurosci Lett 198 (1995) 9
7. Olivar T., and Laird J.M. Differential effects of N-methyl-D-aspartate receptor blockade on nociceptive somatic and visceral reflexes. Pain 79 (1999) 67
8. Laird J.M., Roza C., and Cervero F. Spinal dorsal horn neurons responding to noxious distension of the ureter in anesthetized rats. J Neurophysiol 76 (1996) 3239
9. Baik E.J., Jeong Y., Nam T.S., Kim W.K., and Paik K.S. Mechanism of transmission and modulation of renal pain in cats: effect of nucleus raphe magnus stimulation on renal pain. Yonsei Med J 36 (1995) 348
10. Shafik A. Demonstration of a "renogastric reflex" after rapid distension of renal pelvis and ureter in nonanesthetized patients. Urology 53 (1999) 38
11. El-Nahas A.R., El-Assmy A.M., Shoma A.M., Eraky I., El-Kenawy M.R., and El-Kappany H.A. Self-retaining ureteral stents: analysis of factors responsible for patients' discomfort. J Endourol 20 (2006) 33
12. Heid F., and Jage J. The treatment of pain in urology. BJU Int 90 (2002) 481
13. Laird J.M., Roza C., and Cervero F. Effects of artificial calculosis on rat ureter motility: peripheral contribution to the pain of ureteric colic. Am J Physiol 272 (1997) R1409
14. Jerde T.J., Calamon-Dixon J.L., Bjorling D.E., and Nakada S.Y. Celecoxib inhibits ureteral contractility and prostanoid release. Urology 65 (2005) 185
15. Pruthi R.S., Kouba E., Carson III C.C., and Wallen E.M. Cyclooxygenase-2 inhibitors and other NSAIDs in urology: current peril or future promise?. Urology 68 (2006) 917
16. Norregaard R., Jensen B.L., Topcu S.O., Nielsen S.S., Walter S., Djurhuus J.C., et al. Cyclooxygenase type 2 is increased in obstructed rat and human ureter and contributes to pelvic pressure increase after obstruction. Kidney Int 70 (2006) 872
17. Fujinaka H., Miyazaki Y., Matsusaka T., Yoshida H., Fogo A.B., Inagami T., et al. Salutary role for angiotensin in partial urinary tract obstruction. Kidney Int 58 (2000) 2018
18. Santis W.F., Peters C.A., Yalla S.V., and Sullivan M.P. Ureteral function is modulated by a local renin-angiotensin system. J Urol 170 (2003) 259
19. Walsh T.D., and West T.S. Malignant ureteric obstruction relieved by dexamethasone. Postgrad Med J 60 (1984) 437
20. Hamdy F.C., and Williams J.L. Use of dexamethasone for ureteric obstruction in advanced prostate cancer: percutaneous nephrostomies can be avoided. Br J Urol 75 (1995) 782
21. Scheel Jr. P.J., Piccini J., Rahman M.H., Lawler L., and Jarrett T. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. J Urol 178 (2007) 140
22. Sahin A., Erdemli I., Bakkaloglu M., Ergen A., Basar I., and Remzi D. The effect of nifedipine and verapamil on rhythmic contractions of human isolated ureter. Arch Int Physiol Biochim Biophys 101 (1993) 245
23. Achar E., Achar R.A., Paiva T.B., Campos A.H., and Schor N. Amitriptyline eliminates calculi through urinary tract smooth muscle relaxation. Kidney Int 64 (2003) 1356
24. Du S., Araki I., Mikami Y., Zakoji H., Beppu M., Yoshiyama M., et al. Amiloride-sensitive ion channels in urinary bladder epithelium involved in mechanosensory transduction by modulating stretch-evoked adenosine triphosphate release. Urology 69 (2007) 590
25. Wanajo I., Tomiyama Y., Tadachi M., Kobayashi M., Yamazaki Y., Kojima M., et al. The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics. Urol Res 33 (2005) 409
26. Castroman P.J., and Ness T.J. Ketamine, an N-methyl-D-aspartate receptor antagonist, inhibits the spinal neuronal responses to distension of the rat urinary bladder. Anesthesiology 96 (2002) 1410
27. Radecka E., Magnusson M., and Magnusson A. Survival time and period of catheterization in patients treated with percutaneous nephrostomy for urinary obstruction due to malignancy. Acta Radiol 47 (2006) 328
28. Wong L.M., Cleeve L.K., Milner A.D., and Pitman A.G. Malignant ureteral obstruction: outcomes after intervention. Have things changed?. J Urol 178 (2007) 178
29. Chapman M.E., and Reid J.H. Use of percutaneous nephrostomy in malignant ureteric obstruction. Br J Radiol 64 (1991) 318
30. Markowitz D.M., Wong K.T., Laffey K.J., Bixon R., Nagler H.M., and Martin E.C. Maintaining quality of life after palliative diversion for malignant ureteral obstruction. Urol Radiol 11 (1989) 129
31. Eyre R.C., Benotti P.N., Bothe A., Cady B., and Steele Jr. G. Management of the urinary tract involved by recurrent cancer. Arch Surg 122 (1987) 493
32. Ku J.H., Lee S.W., Jeon H.G., Kim H.H., and Oh S.J. Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences?. Urology 64 (2004) 895
33. Wilson J.R., Urwin G.H., and Stower M.J. The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl 87 (2005) 21
34. Joshi H.B., Stainthorpe A., MacDonagh R.P., Keeley Jr. F.X., Timoney A.G., and Barry M.J. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 169 (2003) 1065
35. Joshi H.B., Stainthorpe A., Keeley Jr. F.X., MacDonagh R., and Timoney A.G. Indwelling ureteral stents: evaluation of quality of life to aid outcome analysis. J Endourol 15 (2001) 151
36. Hruby G.W., Ames C.D., Yan Y., Monga M., and Landman J. Correlation of ureteric length with anthropometric variables of surface body habitus. BJU Int 99 (2007) 1119
37. Jeon S.S., Choi Y.S., and Hong J.H. Determination of ideal stent length for endourologic surgery. J Endourol 21 (2007) 906
38. Duvdevani M., Chew B.H., and Denstedt J.D. Minimizing symptoms in patients with ureteric stents. Curr Opin Urol 16 (2006) 77
39. Joshi H.B., Chitale S.V., Nagarajan M., Irving S.O., Browning A.J., Biyani C.S., et al. A prospective randomized single-blind comparison of ureteral stents composed of firm and soft polymer. J Urol 174 (2005) 2303
40. Borin J.F., Melamud O., and Clayman R.V. Initial experience with full-length metal stent to relieve malignant ureteral obstruction. J Endourol 20 (2006) 300
41. Emmert C., Rassler J., and Kohler U. Survival and quality of life after percutaneous nephrostomy for malignant ureteric obstruction in patients with terminal cervical cancer. Arch Gynecol Obstet 259 (1997) 147
42. Schmidbauer J., Kratzik C., Klingler H.C., Remzi M., Lackner J., and Marberger M. Nephrovesical subcutaneous ureteric bypass: long-term results in patients with advanced metastatic disease-improvement of renal function and quality of life. Eur Urol 50 (2006) 1073
43. Gasparini M., Carroll P., and Stoller M. Palliative percutaneous and endoscopic urinary diversion for malignant ureteral obstruction. Urology 38 (1991) 408
44. Chitale S.V., Scott-Barrett S., Ho E.T., and Burgess N.A. The management of ureteric obstruction secondary to malignant pelvic disease. Clin Radiol 57 (2002) 1118
45. Aravantinos E., Karatzas A., Gravas S., Tzortzis V., and Melekos M. Feasibility of percutaneous nephrolithotomy under assisted local anaesthesia: a prospective study on selected patients with upper urinary tract obstruction. Eur Urol 51 (2007) 224